IndustryCompany release

CorMedix to acquire Heron Therapeutics' assets in deal worth about $222.6M upfront

🇺🇸 Heron Therapeutics, Inc. /De/ (HRTX) · Mon 09 Nov 2026

CorMedix has agreed to buy substantially all of Heron's assets, including four hospital-use products for postoperative pain and nausea and vomiting, with closing expected in the first quarter of 2027.

CorMedix and Heron Therapeutics announced on 9 November 2026 that they have signed a definitive asset purchase agreement. Under it, CorMedix will acquire substantially all of Heron's assets.

The assets include four products: ZYNRELEF, used for postoperative pain, and APONVIE, CINVANTI and SUSTOL, which address postoperative nausea and vomiting or chemotherapy-induced nausea and vomiting.

The consideration is $145 million in cash plus 14.58 million CorMedix shares. Heron could also receive up to $55 million through earn-outs and royalties. The summary puts the upfront value at about $222.6 million.

CorMedix plans to fund part of the cash payment with a $75 million draw on a term loan from Pharmakon. Closing is expected in the first quarter of 2027 and depends on clearance under the Hart-Scott-Rodino Act, the US premerger antitrust review regime, and on approval by Heron stockholders.

What it means for your team

  • Regulatory teams should expect marketing authorisation and licence holder details for the four products to change hands only after the deal closes, which is not expected before Q1 2027.
  • Pharmacovigilance and quality teams at partners and suppliers should watch for notices on safety reporting, complaint handling and supply responsibilities during the transition.
  • Market-access and hospital contracting teams should note the pending change of ownership across a portfolio of hospital-use products, with closing conditional on antitrust clearance and a stockholder vote.

Company's press release (SEC filing): Heron Therapeutics, Inc. /De/ ↗

Article written by VigiEye from the official source (Heron Therapeutics, Inc. /De/). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →